Introduction {#Sec1}
============

In 2012, an estimated 229,060 new cases of invasive breast cancer (BC) are expected in the USA, including 2,190 cases occurring in men \[[@CR1]\]. For women with hormone receptor (HR)-positive BC (approximately 70 % of patients with BC), effective treatment options in the metastatic or locally advanced setting are currently limited \[[@CR2],[@CR3]\]. Although substantial decreases in incidence were observed between 2002 and 2003 (largely because of reductions in use of hormone replacement therapy), the annual incidence rate since 2003 remains relatively unchanged \[[@CR4]\]. Metastatic BC represents approximately 5 % of all BC cases \[[@CR4]\], and 39,920 BC deaths are expected in 2012 \[[@CR1]\]. The use of endocrine therapies in the advanced HR-positive BC setting has significantly improved clinical outcomes in women; however, many patients fail to respond to first-line treatment or experience disease progression after an initial response \[[@CR5]--[@CR9]\]. Consequently, the continuing development of novel therapies for the treatment of advanced HR-positive BC remains of significant importance in the area of oncology.

New therapeutic strategies include the use of targeted agents with varying mechanisms of action. As a class, mammalian target of rapamycin (mTOR) inhibitors exhibit significant clinical antitumor activity in a wide variety of cancer types, including renal cell carcinomas (RCC), mantle cell lymphoma, pancreatic neuroendocrine tumors, metastatic sarcomas, and metastatic BC \[[@CR10]--[@CR19]\]. mTOR forms an important component of the phosphoinositide 3-kinase/Akt signaling pathway that mediates cell growth and proliferation, and dysregulation of this pathway is observed in many cancers, including BC \[[@CR20],[@CR21]\].

Oral mTOR inhibitor everolimus (Afinitor®) received approval in 2009 from the US Food and Drug Administration (FDA) for treatment of advanced RCC after failure of sorafenib or sunitinib \[[@CR22]\]. Everolimus received subsequent approval from the FDA for the treatment of advanced pancreatic neuroendocrine tumors that are unresectable, locally advanced, or metastatic and for the treatment of subependymal giant cell astrocytoma associated with tuberous sclerosis complex in patients who require therapeutic intervention but are not amenable to surgery \[[@CR22]\]. In 2012, everolimus was approved by the FDA for the treatment of adults with renal angiomyolipoma and tuberous sclerosis complex not requiring immediate surgery and, in combination with exemestane, for the treatment of advanced HR-positive HER2-negative BC after failure of treatment with letrozole or anastrozole \[[@CR22]\]. The European Medicines Agency has also approved everolimus for the management of tumors and conditions described above. Additionally, low-dose everolimus (Zortress®) in combination with basiliximab and concurrently with reduced doses of cyclosporine and corticosteroids received FDA approval in 2010 for the prevention of organ rejection in kidney transplant recipients \[[@CR23]\] and Certican® (worldwide) in combination with cyclosporine was approved in 2003 for the prevention of organ rejection in heart, liver, and kidney transplant recipients \[[@CR24]\].

More recently, results from the pivotal phase III *B*reast Cancer Trials of *O*ra*l E*ve*ro*limus (BOLERO)-2 study demonstrated everolimus in combination with the endocrine agent exemestane significantly extended progression-free survival (PFS) compared with placebo plus exemestane in women with advanced HR-positive, HER2-negative BC \[[@CR17],[@CR18]\]. Patient-centered strategies should be devised to manage the often-inevitable adverse events (AEs) associated with any specific cancer therapy. In this article, safety data and previous clinical experience will be used as a basis to describe AE management recommendations for patients with BC who receive everolimus.

BOLERO-2 trial summary {#Sec2}
----------------------

BOLERO-2 was a phase III, randomized, double-blind, placebo-controlled, multicenter study. conducted at 189 sites worldwide (NCT00863655) \[[@CR17],[@CR18]\]. A total of 724 patients with postmenopausal advanced HR-positive, HER2-negative BC refractory to previous letrozole or anastrozole were enrolled and those who met the study criteria were randomly assigned (2:1) to receive oral everolimus 10 mg/day plus oral exemestane 25 mg/day (*n* = 485) or placebo plus oral exemestane 25 mg/day (*n* = 239) \[[@CR17],[@CR18]\]. An interim analysis based upon 7.1 months of follow-up determined that everolimus plus exemestane significantly improved PFS compared with exemestane alone (6.9 vs. 2.8 months, respectively; hazard ratio = 0.43; 95 % CI 0.35--0.54, *p* \< 0.001, local assessment) \[[@CR17]\]. With 12 months of median follow-up, PFS based on local investigator radiology assessment was 7.4 months for everolimus plus exemestane versus 3.2 months for exemestane only (hazard ratio = 0.44; 95 % CI 0.36--0.53; *p* \< 0.001) \[[@CR18]\]. Recently, an 18-month follow-up analysis determined that the median PFS was 7.8 months versus 3.2 months (hazard ratio = 0.45; 95 % CI 0.38--0.54, *p* \< 0.001 local assessment) for combination versus exemestane-only therapy, respectively (*p* \< 0.001) \[[@CR25]\]. Overall AEs observed in BOLERO-2 at the interim analysis (7.1 months of follow-up) (Table [1](#Tab1){ref-type="table"}) \[[@CR17]\] were consistent to AE rates observed at the 12- and 18-month follow-ups \[[@CR18],[@CR25]\] as well as with those previously reported with mTOR inhibitors \[[@CR10],[@CR11]\].Table 1Incidence of any-grade AEs occurring in ≥30 % or grade 3 or 4 AEs occurring in ≥3 % of patients enrolled in BOLERO-2 (interim analysis, 7.1 months of follow-up) \[[@CR17]\]Everolimus + exemestane (*n* = 482), %Placebo + exemestane (*n* = 238), %Preferred termAll gradesGrade 3Grade 4All gradesGrade 3Grade 4Stomatitis56801110Infection^a^44422120Rash3610600Fatigue333\<12610Diarrhea302\<11610Dyspnea184091\<1Anemia16514\<1\<1Aspartate aminotransferase increased133\<1610Hyperglycemia134\<12\<10Pneumonitis1230000Alanine aminotransferase increased113\<1320^a^Data on file, Novartis Pharmaceuticals Corporation. Includes all infections and infestations as defined by CTCAE criteria. Note that all other AEs in this table refer to specific preferred terms outlined by CTCAE criteria \[[@CR47]\]

Potential adverse events encountered by the patient {#Sec3}
---------------------------------------------------

Recognizing the unique AEs associated with anticancer agents allows providers to individualize treatment plans and thereby limit AEs that may decrease a patient's ability to complete a full course of therapy. Oncology professionals involved in the day-to-day care of patients need to accurately recognize AEs associated with specific cancer therapies and incorporate complementary supportive care treatments to monitor, assess, and manage symptoms. Notably, the Oncology Nursing Society (ONS) has played a critical role in evaluating the array of available clinical evidence associated with the treatment of cancer therapy-related AEs. The following discussion of the most commonly observed AEs in the BOLERO-2 study based on the published report \[[@CR17]\] and the proposed management strategies is based on the efforts of the ONS, who provided evidence-based management strategies, together with a current review of the literature.

Class-specific adverse events associated with everolimus combination therapy observed in the BOLERO-2 study {#Sec4}
===========================================================================================================

Stomatitis {#Sec5}
----------

Stomatitis, or oral mucositis, refers specifically to inflammatory diseases of the mouth, including mucosa, dentition, periapical abscesses, and periodontium. Such ailments can impair a patient's ability to eat, swallow, and talk and can cause significant pain. Stomatitis is characterized by ulceration in the oroesophageal mucosa, resulting in pain, erythema, dysphagia, and occasionally bleeding \[[@CR26],[@CR27]\]. Onset typically occurs early (≤1 month after treatment initiation) and is transient \[[@CR28],[@CR29]\]. The condition is also a common toxicity associated with chemotherapy or radiation therapy, occurring as nonspecific ulcerations for which localized palliative treatments and systemic analgesics are generally applied \[[@CR28],[@CR30]\]. In contrast to stomatitis associated with chemotherapy or radiation therapy, stomatitis associated with mTOR therapy has an inflammatory component often clinically mimicking aphthous stomatitis (commonly known as canker sores) and is differentiated from lesions of viral etiology by their localization to the nonkeratinized movable oral and oropharynx mucosa, as opposed to the mucosa of the palate, gingiva, or dorsal tongue surface \[[@CR28],[@CR31]\]. These differences also suggest that the aphthous-like lesions observed with mTOR inhibitors differ from the lesions observed with cytotoxic agents \[[@CR28]\], so management strategies to prevent or treat mTOR inhibitor associated stomatitis also must be distinguished.

### Management recommendations {#Sec6}

Because stomatitis is a common AE (Table [1](#Tab1){ref-type="table"}) experienced by patients treated with everolimus \[[@CR27]\], prophylactic treatment and early recognition of this AE is highly important. Early and active management includes the promotion of good oral hygiene: consistent, regular, and thorough brushing with a soft toothbrush that is changed on a regular basis; daily flossing; frequent rinsing with bland rinses such as sterile water, normal saline, or sodium bicarbonate; and use of oral moisturizers \[[@CR27],[@CR32]\].

Based on the clinical trial experience with patients treated with everolimus, various management strategies depending on the grade of stomatitis observed are recommended (Table [2](#Tab2){ref-type="table"}) \[[@CR22]\]. The prescribing information for everolimus specifically recommends that rinse formulations that contain alcohol should be avoided \[[@CR22]\]. The use of toothpastes that are strong-flavored and that contain sodium lauryl sulfate are not advised; milder, sodium lauryl sulfate-free toothpaste (e.g., children's flavors) should be used instead \[[@CR28]\]. Overall, oncology nurses should work to promote an oral program that addresses basic oral needs to help reduce the amount of microbial flora, reduce pain and bleeding, and prevent infection. Patients also should be advised to avoid acidic, spicy, and hard or crunchy foods and to consume foods that are tepid rather than hot in temperature to prevent the potential for mechanical injury \[[@CR28],[@CR30]\].Table 2Recommended clinical management strategy: stomatitis \[[@CR22]\]GradeSymptomsManagementEverolimus dose modification1Minimal (normal diet)• Manage with nonalcoholic or salt water (0.9 %) mouth wash several times a day• No dose adjustment required2Symptomatic but can eat and swallow modified diet• Temporary dose interruption until recovery to grade ≤1• Manage with topical analgesic mouth treatments (e.g., benzocaine, butyl aminobenzoate, tetracaine hydrochloride, menthol, or phenol) with or without topical corticosteroids (i.e., triamcinolone oral paste)• Reinitiate everolimus at the same dose• If stomatitis recurs at grade 2, interrupt dose until recovery to grade ≤1. Reinitiate everolimus at a lower dose• Avoid agents containing alcohol, hydrogen peroxide, iodine, and thyme derivatives3Symptomatic and unable to adequately eat or hydrate orally• Temporary dose interruption until recovery to grade ≤1. Reinitiate everolimus at a lower dose4Severe (symptoms are life threatening)• Discontinue everolimus and treat with appropriate medical therapy

Early recognition and immediate effective treatment of stomatitis is essential to reduce the number and severity of ulcers. Although experience in managing everolimus-associated stomatitis is limited, it is recommended that topical corticosteroids and mouthwashes be used, similar to those managed with chemotherapy induced stomatitis \[[@CR27]\]. Consistently, standard treatment options include topical high-potency corticosteroids (e.g., dexamethasone, 0.1 mg/mL; clobetasol gel, 0.05 %), topical nonsteroidal anti-inflammatories (e.g., amlexanox, 5 % oral paste), and topical anesthetics ("miracle" or "magic" mouthwashes typically containing viscous lidocaine, diphenhydramine, and an antacid such as aluminum hydroxide or magnesium hydroxide), and nonimidazole antifungals also may be appropriate for some patients \[[@CR27],[@CR28]\]. Agents containing hydrogen peroxide, iodine, and thyme derivatives should be avoided in patients with stomatitis \[[@CR22],[@CR27]\]. [l]{.smallcaps}-Lysine 500 mg/day orally, originally used for recurrence of herpes simplex infections, may also be beneficial in patients with recurring oral ulcers \[[@CR33]\].

Rash {#Sec7}
----

Rash induced by treatment with mTOR inhibitors (Table [1](#Tab1){ref-type="table"}) typically occurs as maculopapular or papulopustular lesions, often with pruritus, and erythematous papules or pustules usually constitute the primary lesion morphology \[[@CR34],[@CR35]\]. Rash primarily occurs on the trunk, scalp, face, and neck, with extremities commonly involved \[[@CR34],[@CR35]\]. The condition generally appears during the first months of everolimus treatment and is most often grade 1 to 2 in severity \[[@CR34],[@CR35]\].

### Management recommendations {#Sec8}

Patient awareness and early intervention is important for managing rash. Patients should be informed of the possibility of developing rash and should promptly report the first signs or symptoms in order to initiate early intervention \[[@CR35]\]. Patients should also be educated on the need for moisturizing frequently; using a thick, alcohol-free emollient cream such as Eucerin®, Aquaphor®, or Cetaphil®; taking short, lukewarm showers; using mild moisturizing, fragrance-free soap; and bathing in lukewarm water with one to two cups of baking soda or Aveeno® bath treatment added to the water \[[@CR36]\]. Patients should also be advised to use a sunscreen of SPF 15 or higher, preferably containing zinc oxide or titanium dioxide, in order to minimize sun exposure \[[@CR36]\]. Management strategies when rash develops should be based on clinical phenotype \[[@CR35]\]. For grade 1 papulopustular rash, a course of topical low- to moderate-strength corticosteroid and topical antibiotics should be sufficient; for grade 3 or intolerable grade 2 rashes, oral antibiotics for 2 to 4 weeks are advocated. For grade 1 maculopapular rash, topical low- to moderate-strength corticosteroids and oral antihistamines should be considered; for grade 3 or intolerable grade 2 rashes, oral corticosteroids and dose reduction/interruption may be required \[[@CR35]\].

Hyperglycemia {#Sec9}
-------------

Hyperglycemia is characterized by an abnormally high concentration of glucose in the blood plasma. According to the American Diabetes Association, this is generally a fasting glucose level \>130 mg/dL or postprandial level \>180 mg/dL \[[@CR37]\]. Symptoms of hyperglycemia include frequent urination, increased thirst, fatigue, blurred vision, weight loss, headaches, and difficulty concentrating. A common toxicity associated with treatment with mTOR inhibitors (Table [1](#Tab1){ref-type="table"}), hyperglycemia is generally well tolerated with a low incidence of treatment discontinuation among patients with cancer \[[@CR10],[@CR17],[@CR38],[@CR39]\].

### Management recommendations {#Sec10}

Monitoring of fasting serum glucose is recommended before the start of anticancer therapy and periodically thereafter \[[@CR27]\]. Optimal glycemic control should be achieved before initiating therapy with an mTOR inhibitor and the patient be made aware of symptoms that may develop. For patients with glucose levels greater than the upper limit of normal (160 mg/dL; grade 1 hyperglycemia), no treatments or dose modifications are recommended \[[@CR27]\]. Patients with glucose levels of \>160--250 mg/dL (grade 2), \>250--500 mg/dL (grade 3), or \>500 mg/dL (grade 4) should be treated according to the American Diabetes Association and European Association for the Study of Diabetes consensus algorithm (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR27],[@CR40]\].Fig. 1American Diabetes Association and European Association for the Study of Diabetes consensus approach for the treatment of hyperglycemia \[[@CR40]\]. Reinforce lifestyle intervention at every visit. ^a^Check HbA~1c~ every 3 months until HbA~1c~ is \<7 %, and then at least every 6 months. ^b^Associated with increased risk of fluid retention, congestive heart failure, and fractures. Rosiglitazone, but probably not pioglitazone, may be associated with an increased risk of myocardial infarction. ^c^Although three oral agents can be used, initiation and intensification of insulin therapy is preferred based on effectiveness and lower expense. With kind permission from Springer Science Business Media: Diabetologia. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy---update regarding the thiazolidinediones, 51:2008; 8--11, Nathan, DM, Buse, JB, Davidson MB, et al.; Fig. 1 © Springer-Verlag

As a general strategy, a patient who develops hyperglycemia should be recommended to drink plenty of water, exercise regularly, and reduce dietary amounts of carbohydrates and sugar \[[@CR37]\]. In severe cases of hyperglycemia, oral antidiabetics may be administered \[[@CR37],[@CR41]\].

Noninfectious pneumonitis {#Sec11}
-------------------------

Noninfectious pneumonitis is a class effect of mTOR inhibitors (Table [1](#Tab1){ref-type="table"}) characterized by a nonmalignant infiltration of the lungs \[[@CR42]--[@CR44]\]. Current evidence suggests this agent-related condition may be immunologically mediated \[[@CR27],[@CR44]\]. Nonspecific respiratory signs and symptoms of pneumonitis include cough, dyspnea, hypoxia, and occasionally pleural effusion, although some patients remain asymptomatic. Common radiographic changes observed with mTOR inhibitor-associated pneumonitis include ground-glass opacities and focal consolidation, predominantly in the lower lobes \[[@CR42],[@CR44]\].

### Management recommendations {#Sec12}

For patients with respiratory symptoms (cough, dyspnea during exertion or at rest) or with documented multiple lung metastases, a baseline computed tomography scan and pulmonary function tests should be performed before initiation of treatment with everolimus. If predicted single breath transfer factor is \<40 %, everolimus therapy should not be initiated until pulmonary function test results have normalized \[[@CR27]\]. If no pulmonary compromise exists, baseline computed tomography scans may be obtained at the physician's discretion \[[@CR27]\]. The potential diagnosis of noninfectious pneumonitis should also be investigated in patients with nonspecific respiratory signs and symptoms during everolimus treatment. Radiographic imaging should be performed and bronchoalveolar lavage may be useful to rule out infection and evaluate lung inflammation \[[@CR27]\]. Therapy should be interrupted and corticosteroid treatment initiated if a patient's symptoms are moderate to severe \[[@CR27]\]. Upon resolution of these symptoms, everolimus can be reinitiated at a reduced dose of 5 mg/day. The everolimus package insert also contains a clinical management strategy for the treatment of everolimus-related noninfectious pneumonitis (Table [3](#Tab3){ref-type="table"}) \[[@CR22]\].Table 3Recommended clinical management strategy: noninfectious pneumonitis \[[@CR22]\]GradeSymptomsManagementEverolimus dose modification1Asymptomatic (radiographic findings only)• Initiate appropriate monitoring• No dose adjustment required2Symptomatic, not interfering with ADLs• Rule out infection• Consider interruption of therapy until symptoms improve to grade ≤1• Consider treatment with corticosteroids• Reinitiate everolimus at a lower dose• Discontinue treatment if failure to recover within 4 weeks3Symptomatic, interfering with ADLs; oxygen required• Rule out infection• Hold treatment until recovery to grade ≤1• Consider treatment with corticosteroids• Consider reinitiating everolimus at a lower dose. If toxicity recurs at grade 3, consider discontinuation4Life threatening; ventilatory support indicated• Discontinue everolimus*ADL* activity of daily living

Infection {#Sec13}
---------

Infection is a common AE reported in patients treated with everolimus (Table [1](#Tab1){ref-type="table"}) \[[@CR22],[@CR34]\]. The innate immunosuppressive properties of everolimus may predispose patients to bacterial, fungal, viral, or protozoal infections including pneumonia, sepsis, mycobacterial infections, aspergillosis, candidiasis, and reactivation of the hepatitis B virus. In the phase III RECORD-1 trial of everolimus (10 mg/day) in advanced RCC, everolimus-related severe infection was reported, including infection associated with fatal respiratory failure or sepsis. In BOLERO-2, sepsis caused two deaths \[[@CR17]\]. Therefore, professionals should be vigilant in evaluating for signs and symptoms of infection with immediate appropriate treatment taken.

### Management recommendations {#Sec14}

In order to identify patients at greater risk for developing infection, a full medical history of prior infection should be obtained and laboratory tests conducted before commencing everolimus therapy including fungal, hepatitis, HIV, tuberculosis, and any other opportunistic infections or pulmonary conditions. Based on results from RECORD-1, a clinical management strategy has been outlined by an advisory panel for the treatment of grade 1 to 4 infection (Table [4](#Tab4){ref-type="table"}). Patients with evidence of fungal infection should be comprehensively treated before everolimus initiation. If an invasive systemic fungal infection is suspected during treatment, everolimus should be immediately withdrawn and the patient treated with an appropriate antifungal \[[@CR27],[@CR45]\]. For patients with hepatitis B virus infection, hepatitis B virus DNA should be monitored and antiviral prophylactic treatment given to prevent reactivation \[[@CR27],[@CR45]\]. Current guidelines recommend the use of high-potency and high-genetic barrier agents to quickly suppress viremia while reducing progression of hepatic damage and the potential for developing resistant mutants \[[@CR45]\].Table 4Recommended clinical management strategy: infections \[[@CR22], [@CR27]\]GradeDescriptionInterventionEverolimus dose adjustment1None• Institute adequate treatment of infection with antibiotics, as appropriate• If toxicity is tolerable, no dose adjustment required• Perform culture and be aware of atypical infections• Initiate appropriate medical therapy and monitor2Localized infection, with local intervention indicated• If toxicity is tolerable, no dose adjustment required• In patients who test positive for hepatitis B surface antigen, consider prophylaxis with entecavir or tenofovir• Initiate appropriate medical therapy and monitor• If toxicity becomes intolerable, temporary dose interruption until recovery to grade ≤1. Reinitiate everolimus at the same dose• If toxicity recurs at grade 2, interrupt everolimus until recovery to grade ≤1. Reinitiate everolimus at a lower dose3IV antibiotic, antifungal, or antiviral intervention indicated; interventional radiology or surgery indicated• Provide IV antibiotic, antifungal^a^, or antiviral therapy; institute additional interventions as for grade 1• Temporary dose interruption until recovery to grade ≤1• Initiate appropriate medical therapy and monitor• Consider reinitiating everolimus at a lower dose. If toxicity recurs at grade 3, consider discontinuation4Life-threatening consequences such as septic shock, hypotension, acidosis, or necrosis• Provide appropriate standard therapy, as for grade 1• Discontinue everolimus*IV* intravenous^a^If diagnosis of invasive systemic fungal infection is made, everolimus therapy should be promptly and permanently discontinued. Avoid coadministration of everolimus with strong cytochrome 3A4 inhibitors

General adverse events observed in the BOLERO-2 study {#Sec15}
=====================================================

In addition to observing key AEs associated with mTOR inhibitors, other AEs were observed in ≥30 % (mostly grade 1 and 2) or grade 3/4 AEs reported in ≥3 % of patients treated with everolimus combination therapy (Table [1](#Tab1){ref-type="table"}) \[[@CR17]\]. Most of these AEs are typically observed when treating cancer patients.

Fatigue {#Sec16}
-------

Cancer-related fatigue is defined as a distressing, persistent, and subjective sense of tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning \[[@CR46]\]. In clinical trials, fatigue is frequently graded using the National Cancer Institute Common Toxicity Criteria \[[@CR47]\], whereas in clinical practice, the ONS grades fatigue from 0 to 10: with 0 being no fatigue and 10 representing the worst fatigue \[[@CR48]\]. The ONS and National Comprehensive Cancer Network identifies exercise as a key intervention for preventing and treating cancer-related fatigue as supported by strong clinical evidence \[[@CR48]\]. Other measures that are suggested to provide benefit in preventing and managing fatigue are nutrition consultation, energy conservation and sleep therapy, stimulus control therapy, strategies to reduce cognitive-emotional arousal, and progressive muscle relaxation training (e.g., relaxation breathing, yoga) \[[@CR46],[@CR48]\].

Diarrhea {#Sec17}
--------

Diarrhea is a common AE associated with cancer treatment. Nonpharmacologic and pharmacologic interventions can be used to control diarrhea and careful serial evaluation to rule out significant volume depletion or comorbidities that would require specific intervention or hospitalization \[[@CR49],[@CR50]\]. Nonpharmacologic interventions include dietary modifications (ceasing the consumption of alcohol and of lactose-containing foods; eating frequent small meals) and aggressive oral rehydration with fluids that contain water, salt, and sugar \[[@CR49],[@CR50]\]. Pharmacologic intervention typically includes loperamide. More severe cases may require hospitalization in order to provide more aggressive treatments \[[@CR49],[@CR50]\].

Dyspnea {#Sec18}
-------

Dyspnea is breathing discomfort of varying intensity or an uncomfortable sensation or awareness of breathing \[[@CR51],[@CR52]\]. The causes of the condition in a patient with advanced cancer may be multifactorial and can be classified as indirect tumor effects (e.g., pneumonia, anemia) or direct tumor effects (e.g., primary/metastatic parenchymal lung involvement), treatment-related factors (e.g., radiation pneumonitis), or factors unrelated to cancer (e.g., comorbidities such as asthma, cardiac ischemia, or psychosocial pain). Pharmacologic agents may be considered and nonpharmacologic intervention methods include patient positioning (e.g., sitting upright in bed or in a chair), scheduling activities, keeping the room cool, having gentle air flow on the patient, promoting relaxation, and psychosocial support \[[@CR53]\].

Anemia {#Sec19}
------

Anemia, a deficiency in red blood cells (RBCs), frequently occurs among cancer patients, and has been shown to negatively impact survival and increase the risk of fatigue in patients \[[@CR54]\]. The European Cancer Anaemia Survey defines anemia as hemoglobin levels ≤12 g/dL \[[@CR55]\], whereas the National Comprehensive Cancer Network guidelines define anemia as hemoglobin levels ≤11 g/dL, or ≤2 g/dL below baseline \[[@CR56]\]. Transfusions with packed RBCs can be a rapid and reliable method of treating anemia; however, such transfusions are associated with patient risks such as transfusion-related reactions, congestive heart failure, bacterial contamination, viral infections, and iron overload \[[@CR56], [@CR57]\]. An alternative strategy includes the use of erythropoiesis-stimulating agent therapy. However, synthetic human recombinant human erythropoietin can stimulate erythropoiesis even in patients with low RBC levels. Hence, FDA has included a "black box" warning stating that erythropoiesis-stimulating agents should be used only to treat chemotherapy-induced anemia and discontinued once chemotherapy has been completed \[[@CR56]\]. Iron supplementation is also generally required by most patients to ensure optimal erythropoiesis \[[@CR58]\] and depending on iron status intravenous iron supplementation (low molecular weight iron dextran, ferric gluconate, or iron sucrose) administered if iron deficiency is suspected \[[@CR56]\].

Elevated transaminases {#Sec20}
----------------------

Elevated transaminases is the general term used to describe elevation of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels; elevations of less than five times the upper limit of normal are considered mild \[[@CR59],[@CR60]\]. Hepatoxic medications and alcohol should be discontinued and any conditions that may cause elevated transaminase levels, such as diabetes, heart disease, and thyroid disease, identified and treated accordingly \[[@CR59]\]. For patients with mild hepatic impairment (Child--Pugh class A), everolimus dose should be reduced to 7.5 mg/day. For moderate hepatic impairment (Child--Pugh class B), everolimus dose should be reduced to 5 mg/day \[[@CR22]\]. In severely hepatic impaired patients (Child--Pugh class C), a dose of 2.5 mg/day may be administered if the desired benefit outweighs the risk \[[@CR22]\].

Conclusions {#Sec21}
===========

The oral mTOR inhibitor everolimus has demonstrated significant clinical efficacy in women with advanced HR-positive BC. In this patient population, everolimus is generally well tolerated, and treatment-related AEs are manageable with appropriate care. The critical and diverse roles of the health care provider should not be underestimated and include the responsibilities of patient education, early AE identification, pretreatment planning, monitoring during therapy, and effective treatment when AEs occur. AEs observed in patients with BC appear to be consistent with those in patients with RCC, for which everolimus is already approved and used routinely in the clinic. As the application of everolimus in the treatment of cancer expands, appropriate management of treatment-related AEs will be fundamental to improving patient quality of life and treatment outcomes.
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